Faeth Therapeutics, Inc. (FTH) Stock Forecast
FTH analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.79 / 5 from 14 analysts
- Price target
- $56.14 average of analyst targets
- Upside to target
- +198.6% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.66
- 52-week range
- $7.89 – $40.05
FTH analyst ratings
14 analystsNumber of analysts at each rating.
FTH price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FTH earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.71 | −$0.77 | −$0.66 | −$3.62 | +75.6% | 2 |
| Current fiscal year (2026) | −$9.97 | −$15.58 | −$2.36 | −$16.72 | −61.4% | 3 |
| Next fiscal year (2027) | −$3.67 | −$4.96 | −$2.03 | −$9.97 | +63.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FTH revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 12 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 13 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 13 |
FTH EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FTH EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0.00 | −$0.66 | −$0.66 | −$0.71 | −$0.71 | — | 0 up · 0 down |
| Current fiscal year (2026) | $0.00 | −$11.98 | −$13.78 | −$13.78 | −$9.97 | — | 1 up · 0 down |
| Next fiscal year (2027) | $0.00 | −$4.96 | −$4.49 | −$4.49 | −$3.67 | — | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FTH earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FTH beat in 7 of 10.
What analysts expect from FTH
14 analysts cover Faeth Therapeutics; their consensus rating is strong buy (4.79 on a 1–5 scale, where 5 is a strong buy). The average price target is $56.14, 198.6% above the latest close of $18.80. Analysts expect earnings of −$9.97 per share for 2026, −61.4% from a year earlier. For 2027 the average estimate is −$3.67 per share. Faeth Therapeutics beat the EPS estimate in 7 of the last 10 quarters.
Related: FTH income statement, FTH key metrics, FTH chart. See the FTH stock overview for the latest quote and news.
FTH forecast FAQ
What is Faeth Therapeutics's price target?
The average analyst price target for Faeth Therapeutics is $56.14, 198.6% above the latest close of $18.80.
Is Faeth Therapeutics a buy, hold or sell?
Of 14 analysts covering Faeth Therapeutics, 11 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Faeth Therapeutics's EPS forecast?
Analysts forecast −$9.97 per share for 2026 (range −$15.58 to −$2.36); for 2027 the estimate is −$3.67.
When does Faeth Therapeutics report earnings?
Faeth Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.66.
Does Faeth Therapeutics usually beat earnings estimates?
Faeth Therapeutics reported EPS at or above the analyst estimate in 7 of the last 10 quarters.